Literature DB >> 30412203

No added sugar: antibody makers find an upside to 'no fucose'.

Ken Garber.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30412203     DOI： 10.1038/nbt1118-1025

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN： 1087-0156            Impact factor:   54.908


× No keyword cloud information.
  5 in total

1.  Superior in vivo efficacy of afucosylated trastuzumab in the treatment of HER2-amplified breast cancer.

Authors:  Teemu T Junttila; Kathryn Parsons; Christine Olsson; Yanmei Lu; Yan Xin; Julie Theriault; Lisa Crocker; Oliver Pabonan; Tomasz Baginski; Gloria Meng; Klara Totpal; Robert F Kelley; Mark X Sliwkowski
Journal:  Cancer Res       Date:  2010-05-18       Impact factor: 12.701

2.  Genentech's glyco-engineered antibody to succeed Rituxan.

Authors:  Mark Ratner
Journal:  Nat Biotechnol       Date:  2014-01       Impact factor: 54.908

3.  Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity.

Authors:  Robert L Shields; Jadine Lai; Rodney Keck; Lori Y O'Connell; Kyu Hong; Y Gloria Meng; Stefanie H A Weikert; Leonard G Presta
Journal:  J Biol Chem       Date:  2002-05-01       Impact factor: 5.157

4.  The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity.

Authors:  Toyohide Shinkawa; Kazuyasu Nakamura; Naoko Yamane; Emi Shoji-Hosaka; Yutaka Kanda; Mikiko Sakurada; Kazuhisa Uchida; Hideharu Anazawa; Mitsuo Satoh; Motoo Yamasaki; Nobuo Hanai; Kenya Shitara
Journal:  J Biol Chem       Date:  2002-11-08       Impact factor: 5.157

5.  A randomized trial of the efficacy and safety of quilizumab in adults with inadequately controlled allergic asthma.

Authors:  Jeffrey M Harris; Romeo Maciuca; Mary S Bradley; Christopher R Cabanski; Heleen Scheerens; Jeremy Lim; Fang Cai; Mona Kishnani; X Charlene Liao; Divya Samineni; Rui Zhu; Colette Cochran; Weily Soong; Joseph D Diaz; Patrick Perin; Miguel Tsukayama; Dimo Dimov; Ioana Agache; Steven G Kelsen
Journal:  Respir Res       Date:  2016-03-18
  5 in total
  2 in total

1.  In vitro and in vivo efficacy of anti-chikungunya virus monoclonal antibodies produced in wild-type and glycoengineered Nicotiana benthamiana plants.

Authors:  Jonathan Hurtado; Dhiraj Acharya; Huafang Lai; Haiyan Sun; Somanath Kallolimath; Herta Steinkellner; Fengwei Bai; Qiang Chen
Journal:  Plant Biotechnol J       Date:  2019-06-26       Impact factor: 9.803

2.  Novel mechanisms of action contributing to benralizumab's potent anti-eosinophilic activity.

Authors:  Rania Dagher; Varsha Kumar; Alan M Copenhaver; Sandra Gallagher; Mahboobe Ghaedi; Jonathan Boyd; Paul Newbold; Alison A Humbles; Roland Kolbeck
Journal:  Eur Respir J       Date:  2022-03-03       Impact factor: 16.671
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.